Unternehmen
ATXA THERAPEUTICS LTD
ATXA THERAPEUTICS LTD – Unternehmen mit Aktivitäten in Forschung und Innovation.
Forschungsprojekte
- PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH). ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and re…